article
Developing IL-15 superagonists for cancer therapy
Richard Sachse discusses how immunotherapies targeting interleukin 15 (IL-15) signalling can be optimised to enhance their efficacy and limit off-target effects.
List view / Grid view
In Vivo
news
Lethal poxviruses could be rendered harmless with single gene removal
Researchers report that removing the vSLFN gene from the ectromelia virus (ECTV) caused a potent immune response which protected animal models.
news
4-PBA could prevent cytokine storm in severe COVID-19
Scientists explore whether the anti-stress drug, 4-Phenylbutiric acid (4-PBA), could prevent cytokine storms causing respiratory failure in COVID-19 patients.
news
A novel drug target for viral encephalitis therapies
Researchers showed CXCL1 signalling to neutrophils drove brain inflammation in herpes simplex virus (HSV) encephalitis and blocking the protein resulted in less severe disease.
news
Tiny antibody component could treat or prevent SARS-CoV-2
The component, now developed into a drug called Ab8, was highly effective at treating and preventing SARS-CoV-2 infection in animal models.
article
Antibody therapeutics for COVID-19
In 2019, the SARS-CoV-2 coronavirus sparked a global pandemic that is likely to continue into 2021. Effective therapeutics that treat the symptoms of the disease and prevent or treat the underlying viral infection are critically required. To meet this need, the global biopharmaceutical industry is evaluating over 50 monoclonal antibody…
article
Defusing antibody neutralisers in AAV gene therapy
Adeno-associated virus (AAV)-mediated gene therapies allow for the treatment of a growing number of diseases; however, the presence of neutralising antibodies can lead to limitations of this technology, particularly for patients who may be excluded due to these pre-existing or developing neutralising antibodies. Recently, a study was published in Nature…
news
Novel lysin-based antibacterial agent could help combat MRSA
Researchers have engineered F12, a lysin-based antibacterial drug, to have limited negative side-effects and so it can be administered repeatedly without loss of efficacy.
news
Novel CAR T-cell therapy could help cure HIV
The designers of the Dual Chimeric Antigen Receptor (CAR) T cell therapy report it slows HIV replication and leads to a smaller viral reservoir in HIV-infected mice.
news
Novel GI tract coating could deliver drugs, aid digestion or control obesity
The developers of a temporary coating which adheres to the small intestine demonstrated it could be modified to deliver drugs, aid digestion and stop absorption of glucose.
news
Novel targeted treatment shows efficacy in treating high-risk solid tumours
The prodrug developed by researchers caused long-term remission in all murine models of high-risk or drug-resistant cancers with fewer side-effects than a comparable drug.
news
Novel alpha-synuclein structures could be the target for future Parkinson’s therapies
Researchers observed new structures of alpha-synuclein aggregates in their study exploring how the presence of cell membrane phospholipids impacts protein aggregation.
news
Toxoplasma gondii hijacks host stress mechanisms to spread through the body
A new study reveals that the Toxoplasma gondii parasite acts through the IRE1 protein to cause infected cells to migrate through the body, spreading the parasite.
news
Novel protein inhibitor improves immunotherapy in squamous cell carcinoma
Researchers reveal a combination of PD1 immunotherapy and BMI1 protein inhibition eliminated cancer stem cells and prevented cancer recurrence in a mouse model.
news
Nanoparticle COVID-19 vaccine elicits immune response in pre-clinical studies
The vaccine candidate repRNA-CoV2S elicited both antibody and T cell responses after just two injections in mice and macaques.
